{"id":472516,"date":"2021-04-07T07:10:17","date_gmt":"2021-04-07T11:10:17","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=472516"},"modified":"2021-04-07T07:10:17","modified_gmt":"2021-04-07T11:10:17","slug":"emerging-markets-report-the-mushroom-movement","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/emerging-markets-report-the-mushroom-movement\/","title":{"rendered":"Emerging Markets Report: The Mushroom Movement"},"content":{"rendered":"
\n

\n
\n
\n An Emerging Markets Sponsored Commentary<\/u>
\n <\/em>
\n <\/a>\n <\/p>\n

ORLANDO, Fla., April 07, 2021 (GLOBE NEWSWIRE) — A short while ago we introduced our readers<\/a> to Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) <\/strong>which is \u201cfocused on finding new ways to treat the profound distress of a world suffering from a mental health crisis\u201d and pursuing \u201cthe tremendous opportunity to bring a new category of psychoactive and psychedelic treatments to market.\u201d<\/p>\n

And while the Company hasn\u2019t issued any news since we last published, significant news in the world of psychedelics and human use has been made. For a Company like Mind Cure Health, positioned at the intersection of psychedelic discovery and human health care, this news could be the beginning of something seismic.<\/p>\n

DC Initiative 81, which passed\u00a0overwhelmingly last fall<\/a>, just went into effect on March 15. Per the\u00a0\u201cEntheogenic Plant and Fungus Policy Act of 2020,\u201d natural psychedelics such as magic mushrooms, ayahuasca, and mescaline are effectively decriminalized<\/a>, making arrests for their possession or use the lowest priority for D.C. police.<\/p>\n

This is a potentially transformative moment for mushroom use and acceptance. One of the largest municipalities in the country is essentially saying it\u2019s ok to use them. And this movement bodes well for companies entrenched in psychedelic development and acceptance.<\/p>\n

It\u2019s simple. Initiatives like this one in D.C. start to take away the spectre of extreme danger and move hearts and minds on reasonable use. Additionally, as with cannabis, legalization in unrestricted states gave fence sitters on the matter a real time case study to see that the relaxation of laws wasn\u2019t making the public crazy or causing an array of other social ills.<\/p>\n

This makes it all that more easier to administer psychedelic therapeutics to patients who once viewed mushrooms and other psychedelics through a much different lens.<\/p>\n

Remember, Mind Cure\u2019s focus is on three key psychedelic divisions: direct to consumer products, technology with their iSTRYM and Psycollage platforms, and psychedelic research and drug development. They also have a strategic investment in clinics. Leveraging big data and cutting edge technology, MINDCURE is transforming mental health and pain treatment.<\/p>\n

And if cannabis is precedent for the advent and acceptance of the amazing mushroom, D.C. is likely just the first of many substantial regulatory walls to fall as Mind Cure prepares its product portfolio for what could soon be an enormous opportunity.<\/p>\n

\n About The Emerging Markets Report:<\/strong>\n <\/p>\n

\n The Emerging Markets Report<\/em> is owned and operated by Emerging Markets Consulting (EMC), a syndicate of investor relations consultants representing years of experience. Our network consists of stockbrokers, investment bankers, fund managers, and institutions that actively seek opportunities in the micro and small-cap equity markets.<\/p>\n

For more informative reports such as this, please sign up at http:\/\/www.emergingmarketsllc.com\/newsletter.php<\/a><\/p>\n

\n Must Read OTC Markets\/SEC policy on stock promotion and investor protection<\/strong>\n <\/p>\n